Simon Waters

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer

Sara A. Hurvitz, Rachel M. Layman, Giuseppe Curigliano, Fabrice André et autres

us, it, fr, kr, mx, ar, au, lu, es, gb (code pays fourni par la source)

Abstract PS3-09-13: Adjuvant Abemaciclib in Male Breast Cancer: A UK Multicentre Case Series from the CONCISE Study

A. Ghose, H. Abdallah, Yetunde Owoseni, Akash Maniam et autres

gb (code pays fourni par la source)

Abstract PS2-02-12: Tolerability of Adjuvant Abemaciclib in Older Adults with High-Risk Early Breast Cancer: Multicentre UK Real-World Data from the CONCISE Study

H. Abdallah, Olubukola Ayodele, A. Ghose, Yetunde Owoseni et autres

gb (code pays fourni par la source)

Abstract RF3-05: Tissue-free circulating tumour DNA detection in patients with early triple negative breast cancer from the c-TRAK-TN trial

N. Cunningham, R. J. Cutts, Claire Swift, K. Dunne et autres

gb, us (code pays fourni par la source)

Abstract PS3-07-12: The CONCISE Study : A Pan-UK Real-World Audit of Adjuvant Abemaciclib Use in High-Risk Early Breast Cancer

Bahaaeldin Baraka, Aruni Ghose, H. Abdallah, Akash Maniam et autres

gb (code pays fourni par la source)

Supplementary Data from Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers et autres

Data from Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers et autres

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

Gabriel N. Hortobágyi, Aleksandra Łacko, Joohyuk Sohn, F. Melo Cruz et autres

us, pl, kr, br, es, ru, tw, de, ie, au, cn (code pays fourni par la source)

LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial

Peter A. Fasching, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang et autres

de, ru, us, tw, ie, ca, kr, es, cn, au, fr (code pays fourni par la source)

235MO Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE

Samantha M. Loi, Erica Stringer-Reasor, Jean‐Sébastien Frenel, Mattea Reinisch et autres

au, us, fr, de, it, kr, tw, ch, ie, cn (code pays fourni par la source)

Abstract 3781: Tracking triple negative breast cancer (TNBC) evolution in the molecular residual disease (MRD) setting in the c-TRAK TN clinical trial

Maria Coakley, Rosalind Cutts, Prithika Sritharan, Sarah Hrebien et autres

gb (code pays fourni par la source)

Supplementary Table S5 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

Maria Coakley, Guillermo Villacampa, Prithika Sritharan, Claire Swift et autres